retatrutide study news Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide—A Game Changer in Obesity
Description
Dont dispose of needles in the regular trash
Interestingly, the incidence of symptomatic documented hypoglycemia was similar with IGlarLixi and glargine (26 and 24%, respectively) and lower in the lixisenatide group (6%)
Biomed Res
These developments point to a broader therapeutic role for GLP-1s, offering hope for tackling addiction alongside obesity
What to bring to your first check-in If you have a follow-up after your first month, bring a simple summary plus the labs you want to ask about
